Core Points - Zealand Pharma A/S will participate in the Jefferies Global Healthcare Conference on November 19, 2025, with CEO Adam Steensberg leading a fireside chat [1] - A live audio webcast of the event will be available for public access, along with an archived recording on the company's website [2] - Zealand Pharma focuses on the discovery and development of peptide-based medicines, with over 10 drug candidates in clinical development, including two that have reached the market [3][4] Company Overview - Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with operations in the U.S. [4] - The company has established development and commercial partnerships with various pharmaceutical companies for its marketed products [3]

Core Points - Zealand Pharma A/S will participate in the Jefferies Global Healthcare Conference on November 19, 2025, with CEO Adam Steensberg leading a fireside chat [1] - A live audio webcast of the event will be available for public access, along with an archived recording on the company's website [2] - Zealand Pharma focuses on the discovery and development of peptide-based medicines, with over 10 drug candidates in clinical development, including two that have reached the market [3][4] Company Overview - Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with operations in the U.S. [4] - The company has established development and commercial partnerships with various pharmaceutical companies for its marketed products [3]

Core Points - Zealand Pharma A/S will host a conference call on November 13, 2025, at 2:00 pm CET (8:00 am ET) to present its third quarter 2025 financial results [1] - The call will feature key executives including President and CEO Adam Steensberg, CFO Henriette Wennicke, and CMO David Kendall, followed by a Q&A session [2] - Participants can register for the call and access the live audio webcast through provided links, with a recording available post-event on the company's website [3] Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines, with over 10 drug candidates in clinical development, including two that have reached the market and three in late-stage development [4] - The company has established development and commercial partnerships with various pharmaceutical companies for its marketed products [4] - Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma also has a presence in the U.S. [5]

Core Points - Zealand Pharma A/S will host a conference call on November 13, 2025, at 2:00 pm CET (8:00 am ET) to present its third quarter 2025 financial results [1] - The call will feature key executives including President and CEO Adam Steensberg, CFO Henriette Wennicke, and CMO David Kendall, followed by a Q&A session [2] - Participants can register for the call and access the live audio webcast through provided links, with a recording available post-event on the company's website [3] Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines, with over 10 drug candidates in clinical development, including two on the market and three in late-stage development [4] - The company has established development and commercial partnerships with various pharmaceutical companies for its marketed products [4] - Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma also has a presence in the U.S. [5]

Group 1 - European stocks gained as investor sentiment improved due to better-than-expected US personal spending data, despite President Trump's plans to impose tariffs on patented drugs [1] - The Stoxx Europe 600 Index rose at the close, with the healthcare sector recovering to gain 0.1% after Trump's announcement of a 100% duty on patented drugs effective Oct. 1, unless producers build manufacturing plants in the US [1] - Novo Nordisk A/S and Zealand Pharma A/S experienced declines following the tariff announcement [1] Group 2 - European equities have been fluctuating within a narrow range as investors assess the outlook for US interest-rate cuts, with resilient consumer behavior noted [2] - The Federal Reserve's preferred inflation gauge showed slower growth in August compared to the previous month [2] Group 3 - Equity strategist Wolf von Rotberg suggested that the lack of detail in the tariff announcement and the potential limited impact on drug prices may not warrant a reduction in pharma exposure [3] - Portfolio manager Sophie Huynh indicated that the situation could present a good entry point for adding to European stocks rather than shorting them, emphasizing the need to consider the broader context despite potential nervousness in the pharma sector [4]

Core Insights - Zealand Pharma has had an exciting year, highlighted by a significant partnership with Roche, which was established in March and has progressed rapidly towards Phase III for the petrelintide asset [3]. Company Overview - David Kendall has been with Zealand Pharma for 5 years and serves as the Chief Medical Officer, bringing prior experience from Eli Lilly and Amylin Pharmaceuticals [2]. Partnership Highlights - The partnership with Roche is a focal point for Zealand Pharma, with rapid advancements in their metabolism portfolio and the petrelintide asset [3].

Group 1 - The company is pursuing its ambition to become a key player in the growing obesity market [1] - A significant collaboration agreement has been established with Roche regarding the main asset, petrelintide [1] - The focus with Roche is to accelerate the development program for petrelintide [1] Group 2 - Upcoming key data readouts are expected for petrelintide in Phase II and for survodutide, which is licensed to Boehringer in Phase III [1] - The company expresses excitement about the upcoming period and the rapid news flow [1]

Core Viewpoint - Zealand Pharma A/S will host a conference call on August 14, 2025, to present its second quarter financial results for 2025 [1] Group 1: Conference Call Details - The conference call will take place at 2:00 pm CET (8:00 am ET) [1] - Key executives participating in the call include President and CEO Adam Steensberg, CFO Henriette Wennicke, CMO David Kendall, and CCO Eric Cox [2] - A live audio webcast and slide presentation will be available for participants [3] Group 2: Company Overview - Zealand Pharma A/S is a biotechnology company focused on peptide-based medicines, with over 10 drug candidates in clinical development [4] - The company has successfully brought two drug candidates to market and has three candidates in late-stage development [4] - Zealand Pharma has established development and commercial partnerships with various pharmaceutical companies [4] Group 3: Company Background - Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, and has a presence in the U.S. [5]

Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines [3][4] - The company has advanced more than 10 drug candidates into clinical development, with two reaching the market and three in late-stage development [3] - Zealand Pharma has development partnerships with several pharmaceutical companies and commercial partnerships for its marketed products [3] Share Capital Information - As of June 30, 2025, Zealand Pharma has a total of 71,343,804 shares, with a nominal value of DKK 1 each [3] - The total share capital and number of voting rights are both reported as 71,343,804 [3][2] - The share capital increase was due to the exercise of employee warrants, as announced in Company Announcement No. 14 / 2025 dated June 6, 2025 [2]

Core Viewpoint - Zealand Pharma A/S announced positive preliminary results for its GLP-1/GLP-2 dual receptor agonist dapiglutide in a Phase I b multi-dose escalation trial, showing significant weight loss without lifestyle interventions [1][4]. Group 1: Trial Results - In the dapiglutide treatment group, participants experienced an average weight loss of 11.6% over 28 weeks, compared to only 0.2% in the placebo group [1][4]. - The trial included 30 participants, predominantly male (approximately 93%), with a median age of 44.5 years and a median starting body mass index (BMI) of 28.8 kg/m² [4][5]. - The trial demonstrated good tolerability at the highest dose of 26 mg, with no severe or serious treatment-related adverse events reported [4][5]. Group 2: Adverse Events - Most adverse reactions were mild gastrointestinal symptoms, such as nausea and vomiting, with two participants withdrawing due to adverse reactions, one related to gastrointestinal discomfort [4][5]. - Injection site reactions were minimal and all were mild, consistent with the profile of similar incretin drugs in other trials [4][5]. Group 3: Drug Mechanism and Future Directions - Dapiglutide is designed to address obesity-related comorbidities driven by chronic low-grade inflammation, combining GLP-1 mediated weight control and GLP-2's improvement of gut barrier function [7]. - Zealand Pharma is advancing a range of differentiated GLP-1 related therapies, including the insulin analog petrelintide, as potential foundational treatments in the weight loss field [4][7]. Group 4: Study Design - The Phase I b trial was a single-center, randomized, double-blind, placebo-controlled study, enrolling participants with a BMI between 27.0 and 39.9 kg/m² [5][6]. - The first part of the trial included 54 participants across three dosage groups, with results indicating an additional weight loss of 8.3% in the dapiglutide group compared to placebo over 13 weeks [5].